FNY Investment Advisers LLC Makes New $173,000 Investment in Eli Lilly and Company (NYSE:LLY)

FNY Investment Advisers LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 210 shares of the company’s stock, valued at approximately $173,000.

A number of other large investors have also modified their holdings of the company. QRG Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 6.2% in the 1st quarter. QRG Capital Management Inc. now owns 126,225 shares of the company’s stock valued at $104,251,000 after buying an additional 7,374 shares in the last quarter. Highline Wealth Partners LLC raised its position in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock worth $57,000 after purchasing an additional 24 shares in the last quarter. Sagespring Wealth Partners LLC lifted its stake in Eli Lilly and Company by 6.7% during the first quarter. Sagespring Wealth Partners LLC now owns 9,389 shares of the company’s stock worth $7,755,000 after purchasing an additional 589 shares during the period. Precedent Wealth Partners LLC acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $211,000. Finally, Great Lakes Retirement Inc. grew its stake in shares of Eli Lilly and Company by 1.9% in the 1st quarter. Great Lakes Retirement Inc. now owns 11,083 shares of the company’s stock valued at $9,154,000 after purchasing an additional 203 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LLY shares. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. Finally, Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $807.62 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a fifty day moving average of $777.10 and a 200-day moving average of $801.77. The firm has a market capitalization of $765.41 billion, a price-to-earnings ratio of 68.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm’s revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 earnings per share. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were issued a dividend of $1.50 per share. The ex-dividend date was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.